医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

TeamBest Global Companies & Best Cyclotron Systems, Inc. Announce Shipment of World’s Very First 6 MeV Proton Cyclotron

2022年01月27日 AM07:18
このエントリーをはてなブックマークに追加


 

OTTAWA, Ontario & VANCOUVER, British Columbia & WASHINGTON & BEIJING

TeamBest Global Companies (TBG) and Best Cyclotron Systems, Inc. (BCS) announce the shipment of the world’s very first 6 MeV Proton Cyclotron, operating in excess of 500 micro amp current, to a National Lab today. The design, development and manufacture was a combined effort of BCS’s Vancouver, Canada facility and Best Theratronics Ltd. manufacturing facility in Ottawa, Canada. This cyclotron is the first of multiple High Current Proton Cyclotrons that the TeamBest Global Companies will be shipping in the coming months of 2022.

BCS is a leader in the design, development and manufacture of novel cyclotrons for production of isotopes and neutron beams for health care institutions, research and academic centers.

For more information about TeamBest Global Companies and Best Cyclotron Systems, please visit:
www.teambest.com
www.bestcyclotron.com
www.theratronics.com
www.bestabt.com
www.bestcure.md

To read most recent news from TeamBest Global Companies, please visit: http://www.teambest.com/news_press.html.

For more information about Krishnan Suthanthiran, please visit his bio page at http://www.teambest.com/about_bio.html.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220126006037/en/

CONTACT

Krishnan Suthanthiran • President & Founder

TeamBest Global Companies & Best Cure Foundation

7643 Fullerton Road, Springfield, VA 22153 USA

+1 703-451-2378

marketing@teambest.com

同じカテゴリーの記事 

  • 日本天皇陛下和皇后出席2024年度日本奖颁奖典礼
  • Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
  • ReNAgade Therapeutics宣布在ASGCT第27届年会上发表演讲
  • ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表
  • BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer